Press release
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
− Product and Pipeline Goals Detail Execution across Four Commercial Brands, Including One Potential Label Expansion, and Ten Clinical Data Readouts From
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n− Product and Pipeline Goals Detail Execution across Four Commercial Brands, Including One Potential Label Expansion, and Ten Clinical Data Readouts From Proprietary and Partner Programs –\n\n− Pipeline Programs and Scientific Innovation Highlighted at R&D Day Exemplify Strength of RNAi Platform and Organic Product Engine –\n\n− Alnylam to Webcast its R&D Day Event Today at 8:30 a.m. ET –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to showcase its R&D progress and platform innovation, as well as its product and pipeline goals for 2023 focused on continued commercial execution of four RNAi therapeutic products, and advancement of early-, mid-, and late-stage investigational programs.\n\n“Throughout 2022, Alnylam has continued to demonstrate the strength of RNAi therapeutics, including the commercial launch of the fifth Alnylam-discovered product within four years, while advancing an organic pipeline of potentially transformative investigational medicines in both rare and common diseases,” said Akshay Vaishnaw, M.D., Ph.D., President of Alnylam. “We expect our track record of strong execution will continue in 2023, with plans to deliver strong commercial performance across four commercial brands, achieve one label expansion, and report ten clinical datasets across Alnylam- and partner-led programs. We believe these milestones will help advance us toward achieving our ‘Alnylam P5x25’ goals of becoming a top tier biotech company over the coming years.”\n\n2023 Product and Pipeline Goals\n\nAlnylam plans to provide guidance on 2023 combined net product revenue for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO® with its fourth quarter and full year 2022 results.\n\nPatisiran, a commercial-stage RNAi therapeutic for the treatment of polyneuropathy in patients with hATTR amyloidosis, and in development for the treatment of the cardiomyopathy of ATTR amyloidosis. Alnylam plans to:\n\n\nAchieve approval from the U.S. Food and Drug Administration (FDA) in late 2023, for the treatment of the cardiomyopathy of ATTR amyloidosis\n\n\nVutrisiran, a commercial-stage RNAi therapeutic for the treatment of polyneuropathy in patients with hATTR amyloidosis, and in development for the treatment of t...